RELEVANCE OF DIAGNOSTICS AND TREATMENT OF BREAST CANCER IN MEN
Abstract
Breast cancer in men is a rare disease, accounting for approximately 0.1% of all malignant breast tumors in men and from 0.6% to 1% of all malignant breast tumors. The incidence of breast cancer in men increases with age for unknown reasons: the average age of men at the time of diagnosis is 67 years, compared with women, whose similar indicator is 57 years. Despite advances in the diagnostics and treatment of breast cancer in women, understanding and strategy for the treatment of breast cancer in men are limited and generally extrapolated from existing knowledge about breast cancer in women. In particular, the molecular subtypes of breast cancer in men have not been studied, although these subtypes have been associated with both biological and clinical features of breast cancer in women. It has been proven that molecular subtypes have an important prognostic value in breast cancer in women. Molecular assessment of tumors plays a significant role in the 22 prescriptions of adjuvant chemotherapy, and therefore the role of genetic testing increases.
References
Ganshina I.P. Application of Herceptin in neoadjuvant and adjuvant treatment of breast cancer patients with HER2 overexpression. In Russian // Pharmateca. Special issue ASCO-2007, P. 13-17.
Garin A.M., Barin I.S. The ten most common malignant tumors. In Russian// Moscow. Max-Press. - 2010 .-- P. 380.
Davydov M.I., Axel E.M. Statistics of malignant neoplasms in Russia and the CIS countries in 2007. In Russian - Bulletin of the RONC named after Blokhin of Russian Academy of Medical Sciences, t. 20, No. 3 (appendix 1), 2009.- P.57.
Merabishvili V.M. Survival of cancer patients. Second edition. Part 1. In Russian// SPb. - 2011 .-- P.350.
Perevodchikova N.I. A guide to the chemotherapy of neoplastic diseases. In Russian // Practical medicine. Moscow / - 2011. - P.512.
Semiglazov V.F., Semiglazov V.V., Dashyan G., Semiglazova T., Manikhas A. Breast cancer treatment strategy based on the identification of biological subtypes. In Russian // Doctor. - 2011. - No. 12. - P.28-34.
Semiglazov V.F., Semiglazov V.V., Dashyan G.A., Paltuev R.M., Migmanova N.Sh., Shchedrin D.E., Grechukhina I.A., Bessonov A.A., Penkov K. D., Merabishvili V.M. Breast cancer in men. In Russian// Pharmateca. - 2010. - No. 6. - T. 200. - P. 40-45.
Semiglazov V.F., Semiglazov V.V., Kletsel A.E. Breast cancer in men. In Russian // Non-invasive and invasive breast tumors. SPb. - 2006 .-- P. 288-299.
Anderson WF, Jatoi I, Tse J, Rosenberg PS. Male breast cancer: a populationbased comparison with female breast cancer. J Clin Oncol 2010;Vol.28:pp.232- 9.
Bazzocchi M, Vianello E, I.inda A, Londero V, Zuiani C. Male breast lesions: which abnormalities really need core needle biopsy? Tumori 2010; Vol.96(2): pp. 266-270.
Bloom KJ, Govil H, Gattuso P, et al. Status of HER-2 in male and female breast carcinoma. Am J Surg 2001; Vol.182: pp.389-92
Boerner S, Fornage BD, Singletary E, et al. Ultrasound-guided fine-needle aspiration (FNA) of nonpalpable breast lesions: a review of 1885 FNA cases using the National Cancer Institute-supported recommendations on the uniform approach to breast FNA. Cancer 1999; Vol.87: pp.19-24.
CC BY-ND
A work licensed in this way allows the following:
1. The freedom to use and perform the work: The licensee must be allowed to make any use, private or public, of the work.
2. The freedom to study the work and apply the information: The licensee must be allowed to examine the work and to use the knowledge gained from the work in any way. The license may not, for example, restrict "reverse engineering."
2. The freedom to redistribute copies: Copies may be sold, swapped or given away for free, in the same form as the original.
